Adient (ADNT) reported $3.69 billion in revenue for the quarter ended September 2025, representing a year-over-year increase of 3.5%. EPS of $0.52 for the same period compares to $0.68 a year ago.
The reported revenue represents a surprise of +1.55% over the Zacks Consensus Estimate of $3.63 billion. With the consensus EPS estimate being $0.55, the EPS surprise was -5.45%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Adient performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Net Sales- Americas: $1.79 billion versus $1.76 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +3.9% change.
- Net Sales- Eliminations: $-26 million compared to the $-19.94 million average estimate based on three analysts. The reported number represents a change of +4% year over year.
- Net Sales- Asia: $783 million versus the three-analyst average estimate of $771.25 million. The reported number represents a year-over-year change of +2.4%.
- Net Sales- EMEA: $1.15 billion compared to the $1.1 billion average estimate based on three analysts. The reported number represents a change of +3.8% year over year.
View all Key Company Metrics for Adient here>>>
Shares of Adient have returned -1.2% over the past month versus the Zacks S&P 500 composite's +1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Adient (ADNT): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
